Absci Corp 8-K

What Happened

• Absci Corporation announced on June 24, 2026 (filed via Form 8-K) that it entered into an underwriting agreement to sell 13,495,277 shares of its common stock to underwriters, at an offering price of $7.41 per share. The offering is expected to close on June 25, 2026 and is being made under a shelf registration statement on Form S-3 declared effective August 22, 2025.

Key Details

• Offering size: 13,495,277 shares priced at $7.41 per share.
• Estimated net proceeds: approximately $93.5 million after underwriting discounts, commissions and estimated expenses.
• Use of proceeds: to fund advancement of ABS-201 (Absci’s AI-designed anti-PRLR antibody) for androgenetic alopecia (pattern hair loss) and endometriosis, and for working capital and general corporate purposes.
• Underwriters: Jefferies LLC, J.P. Morgan Securities LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC; underwriting agreement includes customary representations, conditions, indemnities and market standoff provisions. Legal opinion on share validity from Goodwin Procter LLP was filed as an exhibit.

Why It Matters

• The offering will materially increase Absci’s cash on hand (estimated ~$93.5M net), providing funding specifically earmarked for clinical or development work on ABS-201 and supporting general operations.
• For investors, dilution and share count increase are the main effects to monitor; the filing specifies precise share and price details so holders can estimate dilution and the company’s strengthened cash runway.
• No earnings or executive changes were reported in this filing; the 8-K focuses on capital raising via an underwritten public offering.